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Abstract
Background: Cystic fibrosis (CF) is caused by mutations in the gene encoding for the CF transmembrane conductance
regulator (CFTR) protein, which acts as a chloride channel after activation by cyclic AMP (cAMP). Newborn screening
programs for CF usually consist of an immunoreactive trypsinogen (IRT) assay, followed when IRT is elevated by testing
for a panel of CF-causing mutations. Some children, however, may have persistent hypertrypsinogenemia, only one or
no identified CFTR gene mutation, and sweat chloride concentrations close to normal values. In vivo demonstration of
abnormal CFTR protein function would be an important diagnostic aid in this situation. Measurements of transepithelial
nasal potential differences (NPD) in adults accurately characterize CFTR-related ion transport. The aim of the present
study is to establish reference values for NPD measurements for healthy children and those with CF aged 3 months to
3 years, the age range of most difficult-to-diagnose patients with suspected CF. The ultimate goal of our study is to
validate NPD testing as a diagnostic tool for children with borderline results in neonatal screening.
Methods/Design: We adapted the standard NPD protocol for young children, designed a special catheter for them,
used a slower perfusion rate, and shortened the protocol to include only measurement of basal PD, transepithelial
sodium (Na+) transport in response to the Na+ channel inhibitor amiloride, and CFTR-mediated chloride (Cl-) secretion
in response to isoproterenol, a β-agonist in a Cl- free solution.
The study will include 20 children with CF and 20 healthy control children. CF children will be included only if they carry
2 CF-causing mutations in the CFTR gene or have sweat chloride concentrations > 60 mEq/L or both. The healthy children
will be recruited among the siblings of the CF patients, after verification that they do not carry the familial mutation.
Discussion: A preliminary study of 3 adult control subjects and 4 children older than 12 years with CF verified that the
new protocol was well tolerated and produced NPD measurements that did not differ significantly from those obtained
with the standard protocol. This preliminary study will provide a basis for interpreting NPD measurements in patients
with suspected CF after neonatal screening. Earlier definitive diagnosis should alleviate parental distress and allow earlier
therapeutic intervention and genetic counseling.
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Background
Cystic Fibrosis (CF) is the most frequent life-limiting
autosomal recessive disorder in the white [1]. It is caused
by mutations in 2 alleles of the gene encoding for the CF
transmembrane conductance regulator (CFTR) protein,
which acts mainly as a cyclic AMP (cAMP)-activated chlo-
ride channel [2]. Classic CF is a multisystem disease char-
acterized by elevated chloride concentrations in sweat, fat
maldigestion due to pancreatic exocrine insufficiency, and
chronic bacterial infection in the airways, which leads to
terminal respiratory failure [3]. Newborn screening pro-
grams for CF (CFNBS) began in France 4 years ago
because evidence shows that early diagnosis of this dis-
ease can prevent malnutrition and help to minimize lung
damage [4]. Early diagnosis also allows parents to have
earlier genetic counseling and to choose prenatal diagno-
sis in subsequent pregnancies, since only a minority of
carrier couples can be directly detected. The French CFNBS
is based on the immunoreactive trypsinogen (IRT) assay
on dried blood, followed when IRT is elevated by analysis
for a panel of CF-causing mutations [5]. IRT values tend to
remain elevated for several months in babies with CF,
because pancreatic trypsinogen leaks back through inter-
stitial fluid due to partial obstruction of pancreatic ducts
[6]. In some cases, however, IRT remains elevated even
though CF cannot be formally diagnosed because only
one mutation – or even none – is identified and the
infant's sweat chloride concentration tends towards nor-
mal values [7]. These children may nonetheless develop
symptoms consistent with CF or with a CF-related disor-
der [8]. The lack of specificity of IRT means, however, that
they may also be false positives [9]. This presents a diag-
nostic dilemma. CF should be confirmed or ruled out as
quickly as possible in these situations to alleviate parental
distress and allow earlier therapeutic intervention and
genetic counseling.
Standard diagnostic strategy calls for extensive analysis of
the CFTR gene and repetition of the sweat Cl- measure-
ment [10,11]. Genetic studies, however, take several
weeks and may find no useful information, neither con-
firming nor ruling out CF, such as when one or both
mutant alleles remain unidentified or when the CF-caus-
ing nature of the mutations cannot be proven [12]. Sweat
studies may also be unreliable, because not enough sweat
is collected, or the values are borderline, or both [13].
In vivo demonstration of abnormal CFTR-related ion
transport across nasal epithelium could serve as an impor-
tant diagnostic tool in these difficult situations. Sodium
(Na+) transport and CFTR-related Cl- transport can be
measured electrically by recording the changes in the
nasal transepithelial potential difference (PD) [14]. The
profile of CF patients is characterized by hyperpolariza-
tion of basal PD, increased Na+ channel activity, which
can be detected by evaluating the magnitude of NPD
recorded in the presence of a Na+ channel blocker (amilo-
ride), and defective adenosine cAMP-mediated Cl- secre-
tion, detected by the PD changes in response to β-
adrenergic agonists in a low chloride solution (Figure 1).
Nasal PD (NPD) measurement has been widely validated
in adults [14] and provides a quick, easy, and painless tool
to discriminate between adults with atypical CF and those
presenting some CF symptoms without CF [15,16].
The NPD measurements in infants reported so far come
mostly from case reports [17-19]. These few studies used
either the equipment already validated in adults, or spe-
cially designed one-of-a-kind devices. It is important how-
ever to standardize the protocol and to verify that the
reference data and patterns in infants are similar to the
values previously validated in adults. We do not yet know,
for example, whether airway epithelium undergoes matu-
ration during the first months of life, as renal and sweat
gland epithelia do [13]. Therefore, before this test is
implemented as a diagnostic tool for cases with border-
line observations in neonatal screening, there is an urgent
need to obtain and validate reference data for NPD meas-
urements in infants and very young children with CF and
in healthy controls of the same age.
Objectives
The aim of the study is to establish reference NPD values
for both healthy children and those with CF aged 3
months to 3 years for measurements obtained with a sim-
plified PD protocol and equipment specially designed for
infants.
Material
NPD Device and protocol development in infants and
young children.
The protocol is derived from our previously published
standardized protocol in older children [20].
PD between 2 silver/silver chloride electrodes is measured
with a high input impedance (108–1012 ohm) low resist-
ance voltmeter amplifier (Logan-Sinclair, Kent, UK), elec-
trically isolated from the subject and linked to a
computerized recording system. The skin of the inner
forearm is slight abraded with a hand-held motor unit
containing a diamond-tipped dental burr, to allow direct
access to the subcutaneous space of the forearm and create
a suitable site of zero potential. The reference electrode is
taped over this site, and diluted (1:1) isotonic saline
serum-electrode gel is injected through the hole into the
electrode to allow electrical contact. The electrode is main-
tained in place by spars.BMC Pediatrics 2006, 6:25 http://www.biomedcentral.com/1471-2431/6/25
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The exploring electrode is connected to a nasal catheter
filled with diluted ECG electrode gel. In collaboration
with a manufacturer (Marquat Génie Médical, Boissy St
Léger, France, http://www.marquat.com) specialized in
medical devices, we developed a manufactured single-use
sterile catheter (Figure 2), This specially designed catheter
carries the European Mark, granted by the appropriate
body. The device is composed of a double lumen PVC
tube, 45 cm in length, with an external diameter of 3 mm
and graduated every 0.5 centimetre for about 10 cm from
the distal extremity to control the position of fixation.
One lumen (internal diameter: 1.0 mm) is filled with the
1:1 mixture of electrode gel and provides the bridge linked
to the exploring electrode. The second lumen (internal
diameter: 1.0 mm) allows the perfusion of different solu-
tions by a pump that provides a continuous flow through-
out the perfusion period.
For these measurements, children lie in a supine lateral
recumbent position, either on the bed or in their mother's
arms, with the head slightly elevated. Young children may
require light sedation (intrarectal diazepam 0.5 mg/kg if
younger than 6 months or midazolam 0.3 mg/kg for older
infants). Conductivity of the bridge is assessed by meas-
urements of skin palm PD at the beginning and end of the
test, and acceptable values range from -30 mV upwards.
Nasal PD is recorded in both nostrils as often as possible.
Ringer's perfusion is begun at a rate of 1 ml/min and then
increased according to tolerance to the optimal rate of 3
ml/min. Basal PD is recorded from the mucocutaneous
junction at 2.5 mm intervals along the floor of the nose
during perfusion of the Ringer's solution. The operator
positions the probe at the point of maximal negative volt-
age and holds it in this position throughout the protocol.
After stabilization of basal PD, solutions are perfused in
the following order: (1) 100 μM amiloride (sigma) in
Ion transport in normal and CF nasal epithelium Figure 1
Ion transport in normal and CF nasal epithelium. Nasal PD measurements in a healthy subject and in a CF patient.
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saline solution to block sodium current, (2) chloride-free
solution containing 100 μM amiloride and 10 μM isopro-
terenol (Abbott) to drive chloride secretion and stimulate
the cAMP-dependent CFTR-related Cl- conductance. At the
end of the perfusion of each solution, Ringer's solution is
perfused for 30 seconds to ensure complete replacement
of the liquid bathing the epithelium. Solutions are
changed as soon as a steady voltage tracing is achieved for
at least 45 seconds. The mean plateau voltage values for
the last 30 seconds are taken as the final reading for each
solution. For ease of reading, Δamiloride refers to the dif-
ference in NPD values between the plateau reached during
perfusion with amiloride-containing Ringer's solution
and that reached with amiloride in low chloride solution.
Similarly ΔCl-free-isoproterenol refers to the net change
between the amiloride-containing Ringer's solution and
amiloride plus isoproterenol in low chloride solution.
Both nostrils are explored as often as possible. The com-
position of the Ringer's solution is: NaCl: 8.18 g/l (140
mM); KCl: 0.44 g/l (6 mM); MgCl2 × 6H2O: 0.20 g/l (1
mM); Ca Cl2, 2H2O: 0.30 g/l (2 mM); glucose: 1.80 g/l
(10 mM); and HEPES: 2.38 g/l (10 mM), water PPI qsp
1000 ml. Composition of the chloride-free solution is: Na
Gluconate: 30.54 g/l (140 mM); K Gluconate: 1.44 g/l (6
mM); Mg C12 × 6H2O: 0.20 g/l (1 mM); Ca Cl2 × 2H2O:
0.30 g/l (2 mM); glucose: 1.80 g/l (10 mM); and HEPES:
2.38 g/l (10 mM)water PPI 1000 ml.
Pulse oxymetry and heart rate are monitored throughout
the procedure. Weight is checked at 12 hours and 24
hours in children younger than 6 months. The procedure
is stopped immediately if the child swallows the solution.
Even if the child were to swallow 5 ml of the amiloride
and isoproterenol, this would correspond to 0.5 mg ami-
loride and 0.01 mg of isoproterenol, a minute dose with
no clinical consequences. Children who are sedated may
not leave the hospital until completely awake.
Comparison of the standard method and the method
modified for infants and young children
We compared the standard method and the method mod-
ified for infants in 3 healthy adults and 4 CF patients in a
preliminary study. Each individual's tests were conducted
at least 8 hours apart. The 3 healthy adult volunteers,
mean age 33.3 (3.8) years, were asymptomatic for respira-
tory or gastrointestinal symptoms. They were nonsmokers
with no history of nasal pathology. One healthy control
took the modified test the day after the standard test and
had rhinitis at that time. The mean age of the 4 CF patients
was 15.2 (1.5) years. They all had chronic colonization
with Pseudomonas aeruginosa. The same investigator per-
formed all measurements.
Methods/Design
Patients and controls
This study will include children aged between 3 months
and 3 years recruited from 9 French CF centers in the Paris
area, Normandy, and southern France. Exclusion criteria
for all participants will be upper respiratory tract infection
during the 4 weeks before the study, passive smoking,
atopy, nasal polyps, nasal surgery in the year before the
measurement, and rhinitis or local nasal treatment during
the month before the procedure.
The CF children must carry 2 CF-causing mutations in the
CFTR and/or have a chloride sweat concentration > 60
mEq/L.
The healthy children will be recruited from the siblings of
the CF patients. This strategy was chosen because we
assume that very few healthy children younger than 3
years would normally undergo NPD testing for medical
reasons. We think, however, that parents of children with
CF may well agree to have their healthy child take this test
to help advance research in this disease. Most often, the
siblings of a CF child will have undergone genetic screen-
ing for the familial mutation either at antenatal diagnosis
or after birth. If this is not the case, we will verify that their
IRT level was normal at neonatal screening to decrease the
risk of including heterozygotes and perform genetic test-
ing to verify that they do not carry the familial mutation.
These results will be communicated to the family before
inclusion.
Endpoints
All NPD tests will be performed by the same investigator.
Endpoints for each nostril will be:
Pediatric catheter device Figure 2
Pediatric catheter device.
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￿ mean basal PD value, that is, mean of the PD recordings
from the mucocutaneous junction at 2.5 mm intervals
along the floor of the nose
￿ lowest maximal basal PD as the maximal negative volt-
age
￿ Δamiloride as the differences in NPD values between the
plateau reached during perfusion with amiloride in
Ringer's solution and that reached with amiloride in low
chloride solution
￿ ΔCl-free-isoproterenol as the net change between amilo-
ride in Ringer's solution and amiloride plus isoproterenol
in low chloride solution.
Number of subjects
Table 1 summarizes our reference data from patients aged
5–18 years. The indicator that best discriminates between
patients with and without CF is ΔCl-free-isoproterenol
(15). For these criteria, the reproducibility coefficient
between both nostrils for the same patient is 89%, and
measurement precision is 2.5 mV. The ROC curve shows
the variation of the decision threshold (Figure 3). For ΔCl-
free-isoproterenol = -8 mV, sensitivity is 0.90 and specifi-
city 0.87, whereas sensitivity decreases to 0.8 at ΔCl-free-
isoproterenol = -4 mV (specificity = 1), and to 0.7 for ΔCl-
free-isoproterenol = -2 mV.
For  Δ = 0.05 and a precision of 15%, the minimum
number of subjects for each group is 20.
Ethical considerations
The study was approved by the Necker-Enfants Malades
Ethics Committee, and written informed consent will be
obtained from the parents of each subject.
Because the aim of this study is to validate a diagnostic
tool for cases considered borderline by neonatal screening
for CF, that is, infants or children younger than 3 years,
reference data for children younger than 3 years is essen-
tial. It is inappropriate to rely on values established in
older children because of the possibility of airway epithe-
lial maturation (given that we already know that sweat
gland epithelium matures) (21). This study must there-
fore include children in the same age range as the children
for whom this diagnostic tool may be used.
Statistical analysis
Data will be presented as mean (SEM). Basal NPD, Δami-
loride and Δchloride-free+isoproterenol, from the left
nostril, the right nostril, and the average of both nostrils
will be reported. Comparisons between groups will be
analyzed with the Wilcoxon signed rank test for paired
data and the Mann-Whitney test for unpaired data and
will focus on the average values from both nostrils and on
the nostril demonstrating the best change. A p-value less
than or equal to 0.05 will be considered statistically signif-
icant.
Discussion
Measurements of nasal PD in infants and young children
present a variety of practical problems that this device and
protocol overcome to the extent possible. Because infants
cannot remain still, we shortened the procedure by add-
ing isoproterenol directly in the low chloride perfusate
after the perfusion of amiloride in Ringer's solution and
by defining the steady plateau before perfusion change at
30 rather than 60 seconds, as in the standard method. The
catheters used most frequently until now have been 8-Fr
Foley pediatric urinary catheters modified by cutting the
balloon area and placing it in the distal part or in single-
lumen PE-50 tubing or umbilical vessel catheters (1–4).
Southern and Knowles developed a single lumen polyeth-
ylene 10 tubing threaded over a 30-gauge needle acting
both as electrode and perfusion line. This catheter is not
for single use, however, and requires sterilization. This is
an important limitation because of the risk of bacterial
nasal carriage in CF and in view of international hygiene
recommendations. To reduce the possibility of cross-con-
tamination and minimize patient discomfort, we devel-
oped a single-use, sterile catheter specially designed for
infant NPD in collaboration with a manufacturer special-
izing in biomaterials. The 3-mm diameter was designed
Table 1: Results of NPD measurements in CF patients, heterozygotes for 1 CF mutation and healthy controls.
Variables CF
(n = 37)
Htz
(n = 37)
Ctrls
(n = 29)
p 
CF vs. Htz
p 
CF vs. Ctrls
p 
Htz vs. Ctrls
Baseline NPD(mV) -47(2.6) -15.5(1.3) -15(1.5) <0.0001 <0.0001 0.9
Δamiloride (mV) 24(2.2) 6.2(0.9) 7.1(1.2) <0.0001 <0.0001 0.69
Δchloride-free(mV) 0.5(1.1) -6(0.8) -10.1(1.5) <0.0001 <0.0001 0.01
Δisoproterenol (mV) -1(0.3) -2.5(0.3) -5(0.6) 0.004 <0.0001 0.003
ΔCl-free-Isoproterenol (mV) 1(1.3) -8.2(0.9) -15(1.7) 0.008 <0.0001 0.0002
Data are presented as mean (SEM)
Htz: heterozygotes; Ctrls: healthy controlsBMC Pediatrics 2006, 6:25 http://www.biomedcentral.com/1471-2431/6/25
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for exploration of an infant's nostril. A catheter with a
smaller diameter tends to slip out and could produce inac-
curate measurements. The 1-mm diameter of the inner
lumen allowed correct PD conductance after it was filled
with diluted ECG gel. After extensive testing in our study,
the catheter successfully underwent the procedure for
European Mark approval.
The infant method differs from the standard method
developed for adults in its use of a specially designed cath-
eter, lower perfusion rate (1 ml/mn initially and 3 ml/mn
versus 5 ml/mn at once) and shortened protocol that does
not include the test of a low chloride solution. Volunteers
and patients found both procedures equally tolerable.
NPD values were consistent with previously published
values in healthy subjects and CF patients [14,20].
There were no clinically significant differences between
standard adult and pediatric methods for maximal basal
PD and Δamiloride. Similarly, the response to isoprotere-
nol in low chloride solution was not lower than with the
adult method, thus indicating that the 2 methods provide
comparable results under normal and disease conditions
(Table 2).
Conclusion
Neonatal screening for CF began in France 4 years ago. A
substantial number of cases remain inconclusive because
of intermediate sweat test values and no or only 1 identi-
fied mutation. The differential diagnosis between hetero-
zygosity and CF is clearly crucial in these cases because
some cases will develop atypical CF with fully expressed
pulmonary involvement [8,21,22]. This study will pro-
vide the basis for interpreting findings from a new and
rapid diagnostic tool in patients with suspected CF after
neonatal screening. This should help clinicians to allevi-
ate parental distress and provide earlier therapeutic inter-
ventions and genetic counselling [23].
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